David St. Peter

MPM Bioimpact Inc (MPM Capital) is a venture capital firm founded in 1996 by Ansbert K. Gadicke and Luke B. Evnin. The firm is headquartered in Boston, Massachusetts.

Oscient Pharmaceuticals Corp. is a biopharmaceutical company that sells and markets products to community-based primary care physicians through its primary care sales force in the United States. It markets two products namely, ANTARA fenofibrate capsules, a cardiovascular product and FACTIVE gemifloxacin mesylate tablets, a fluoroquinolone antibiotic. It also has late-stage antibiotic candidate, Ramoplanin for the treatment of clostridium difficile-associated disease. The company was founded on May 09, 1961 and is headquartered in Waltham, MA.

True North Therapeutics, Inc. operates as a biopharmaceutical company. It focuses on the discovery, development, and commercialization of first-in-class product candidates for complement-mediated diseases. The company was founded by Nancy E. Stagliano in 2013 and is headquartered in South San Francisco, CA.

Biointervene, Inc. operates as a biopharmaceutical company. The company was founded by Gary J. Bennett and Daniela Salvemini in 2014 and is headquartered in San Diego, CA.

Star Therapeutics, Inc. is an American company that aims to develop life-changing therapies for rare diseases. The company's mission is to help millions of patients in urgent need. The company was founded by Adam Rosenthal, who has been the CEO since incorporation.

Blade Therapeutics, Inc. offers anti-fibrotic therapies to meet unserved patient needs. Its product portfolio is to address various fibrotic diseases and their underlying pathophysiology. The company was founded by Hal Dietz and Wendye R. Robbins and is headquartered in South San Francisco, CA.

The Scleroderma Research Foundation is a non-profit organization that funds research for scleroderma, a potentially life-threatening illness. The non-profit company is based in San Francisco, CA. Established in 1987 by a patient-turned-activist, the foundation is the largest investor in scleroderma research. The foundation's goal is to find a cure for the disease by bringing together the best minds in science. The SRF has invested over $39 million dollars to date in scleroderma research, funding and facilitating research at top institutions such as Johns Hopkins University School of Medicine, Stanford University, and the University of California.